Optinose Announces Peer-Reviewed Publication Demonstrating Efficacy Of EDS-FLU In Treating Chronic Rhinosinusitis With Or Without Prior Sinus Surgery In ReOpen1 And ReOpen2 Trials
Portfolio Pulse from Benzinga Newsdesk
Optinose has published peer-reviewed results from the ReOpen1 and ReOpen2 trials, demonstrating the efficacy of EDS-FLU in treating chronic rhinosinusitis, with or without prior sinus surgery.
September 05, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Optinose's EDS-FLU has shown efficacy in treating chronic rhinosinusitis, as demonstrated in the ReOpen1 and ReOpen2 trials. This could positively impact the company's stock price.
The publication of positive trial results for EDS-FLU is likely to boost investor confidence in Optinose, potentially leading to a short-term increase in stock price. The trials' success indicates a strong product offering, which is crucial for the company's growth and market position.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90